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Abstract 
 
According to  data of 2018 from the World Health Organisation (WHO), female breast 
and stomach cancers are the second and fifth types of cancers, respectively, in regards 
of new cases (close to 2.1 and 1.0 million new cases each); and are fifth and third when 
speaking of mortality rate (627 and 783 thousand for each).  
Thus, pushing the need for new improved methods of either therapy or, preferably, 
diagnostic. Having an early diagnosis reduces the mortality rate of the patient. 
With the aim of improving cancer diagnosis schemes this dissertation work researches 
the usage of Raman spectroscopy to detect traces of cancer tissues in samples.  
Firstly, a research of the Raman effect was done to better understand the process and 
its limitations. Afterwards a literature review was done on the usage of Raman 
spectroscopy applied to both mammary and digestive tract tissues to help visualize the 
current state of the art, the best practices of the technique in biological samples and the 
kind of data one would be able to expect. 
Human tissue samples acquirement can be a lengthy process. Research was done to 
check if there is a correlation or even better, a way to translate the results obtained using 
a household pet to human cancer. Which was determined to be doable. 
Because of this fact, feline mammary tissue was analysed using the present Raman 
spectroscopy equipment determining the presence of four different types of spectra on 
the samples that were attributed to four different tissues. Two of them being believed to 
be a benign and malign tumour tissues.  
 
Key Words: Raman effect, Raman spectroscopy, mammary tissue, digestive tract, 
cancer, fibre optics, micro structured optical fibres 
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Resumo 
 
De acordo com dados de 2018 da Organização Mundial de Saúde (WHO), os cancros 
da mama e de estômago são os segundos e quintos tipos de cancro, respetivamente, 
em termos de novos casos (aproximadamente 2.1 e 1.0 milhões cada), e são quinto e 
terceiro quando falando de taxa de mortalidade (627 e 783 mil cada um).  
Portanto, criando a necessidade de desenvolver novos ou melhorados métodos de 
terapia ou, preferencialmente, diagnóstico, conseguindo um diagnóstico atempado, 
reduzindo a taxa de mortalidade do paciente.  
Com o objetivo de melhorar os esquemas de diagnóstico de cancro este trabalho de 
dissertação pesquisa o uso de espectroscopia de Raman para detetar traços de tecidos 
cancerígenos em amostras. 
Primeiramente, a pesquisa do efeito Raman foi feita para melhor entender o processo e 
as suas limitações. Após isso uma revisão de literatura foi feita no uso da espectroscopia 
de Raman aplicada a tanto tecidos mamários como do trato digestivo para ajudar a 
visualizar o corrente estado de arte, as boas práticas da técnica em amostras biológicas 
e que tipo de dados se poderia esperar obter. 
Obter amostras de tecido humano pode ser um processo moroso. Pesquisa foi feita para 
averiguar se existe uma correlação ou melhor uma maneira de transladar os resultados 
obtidos usando um animal doméstico para cancro humano. O que foi determinado como 
fazível. 
Devido a este facto, foi analisado tecido mamário felino usando o equipamento de 
espectroscopia de Raman presente. Nele foi determinado a presença de quatro 
espectros diferentes que foram atribuídos a quatro tecidos diferentes. Dos quais dois 
acreditasse serem tecidos tumorais benigno e maligno. 
 
Palavras-chave: Efeito Raman. espectroscopia Raman, tecido mamário, trato 
digestivo, cancro, fibras óticas, fibras óticas micro estruturadas. 
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Chapter 1 – Introduction and Motivation 
 
1. Introduction 
 
In 1930 Sir Chandrasekhara Venkata Raman won the Nobel prize in Physics by 
describing what is now called the Raman effect. Using an analogy with X-ray scattering 
the article describes the effect as being a new type of secondary radiation [1]. 
Raman effect is a second order scattering process [2, 3]. When a photon collides 
with the sample it might either lose energy (called a Stokes shift) or gain energy (anti-
Stokes shift). The coming radiation, either in a transmission or backscatter configuration 
is then analysed. Noting that Raman effect is orders of magnitude less prone to occur 
when comparing to fluorescence. To circumvent that a good choice of wavelength of the 
laser source is of major importance to avoid wavelengths that provide too much 
fluorescence with the sample at question, as it happens when using light in the visible 
spectrum to analyse biological samples.  
Albeit all that, Raman effect provides a label free and quick way to characterize the 
samples at question. Raman spectroscopy applied to biological tissue is already being 
pursued at an academical level, with some pursue for commercial applications. The 
major application, that this dissertation gives focus, is for cancer characterization and 
discrimination in human tissue. From literature reviewed it is already being applied to 
digestive tract malignancies along with breast ones. Also noting other applications in 
other tissues ranging from soft tissues like brain to hard tissues such as bone. Raman 
spectroscopy is also being applied in conjunction with optical fibres enabling the 
development of smaller spectroscopy apparatus. Such developments can be used to 
upgrade current diagnostic techniques in a medical environment. 
 
1.1 Motivation and objectives 
 
This dissertation is being done to a MSc. in Medical Physics, therefore the primary 
motivation for this work is quite straightforward. To utilize known and well understood 
physical phenomena together with advancements in optical fibres to improve tracking of 
diseases as prevention can be seen as more desirable than treatment. 
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 The second motivation point is the fact that Medical Physics is underrepresented in 
this country, so this work is also done with prospects of bringing more relevance to this 
profession while also giving precedence for more research in the implementation of 
optical technologies for disease tracking and prevention. 
For last, curiosity brought motivation. The wanting to know more, how physics is 
applied to medical advancements and wanting to be part of it.  
In order to obtain the desired results and establish the groundwork for further work, 
being that the development of a fibre-based Raman probe that can be integrated with 
modern endoscopy techniques, the primary objectives of this dissertation are the 
following:  
• Study Raman effect and present state of the art medical implementations. 
• Study Raman effect in biological tissues. 
• Differentiate between different tissues using Raman spectroscopy. 
• Attest viability for usage and improvement in current medical solutions. 
1.2 Thesis organization 
 
In Chapter 1, introduction, motivation and objectives are presented to aid the reader 
understand where the foundations of this dissertation work stand upon. Also, the major 
contributions stemming from this work are shown as also the key points to take from this 
chapter. 
In Chapter 2, the research groundwork that the dissertation bases itself off is 
provided. There is a concise introduction to the Raman effect; biomedical 
implementations of Raman spectroscopy are also disclosed; closing the chapter some 
key remarks are emphasised. 
In Chapter 3, the results are represented together with their analysis and discussion. 
On the chapter there is also a reasoning for using household cat mammary tissue is 
written and closing the chapter the key aspects are summed up.  
In Chapter 4, the dissertation conclusions were drawn, future work was also 
envisioned. Such work would have the objective to develop a smaller Raman 
spectroscopy system using novelty types of micro structured optical fibres. 
With that in mind research was done and is present on the Annex chapter. In 
Appendix A, optical fibres are presented together with implementations for Raman 
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spectroscopy shown by works that were found to be relevant for this dissertation and as 
reference for future work.  
 
1.3 Outputs 
 
J. M. R. Jordão, S. Novais, S. F. O. Silva and O. J. R. Frazão, "An overview of fiber-
based Raman spectroscopy for cancer detection", in 4th JEFFA - Jornadas em 
Engenharia Física, Física, Física Médica e Astronomia 2019, Porto, Portugal, May 2019 
 
J. M. R. Jordão, S. Novais, S. F. O. Silva and O. J. R. Frazão, “A brief review of fiber 
optic based Raman spectroscopy for cancer detection”, in DCE/19 3rd Doctoral Congress 
in Engineering, Porto, Portugal, June 2019 
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Chapter 2 – State of the art: Raman effect, 
Biomedical applications 
 
2. Raman effect: introduction 
 
2.1 Principles of Raman Effect 
 
Raman effect was first described in detail by Sir Chandrasekhara Venkata Raman 
in 1928 that disagreed of it being a “feeble fluorescence” but a new type of secondary 
radiation, an optical effect that could be analogue with X-ray scattering [1], earning him 
the Nobel prize in Physics in the year of 1930.   
Raman scattering is an inelastic interaction [3]. When a sample is irradiated with 
light two types of collision might occur: either an elastic one or inelastic, no interaction is 
also possible. If a photon collides with the sample its energy changes causing either a 
red-shift (loses energy, Stokes shift) or a blue-shift (gains energy, anti-Stokes shift). 
Stokes shift is more likely to occur due to practically the entire sample population being 
on the fundamental level, even so both Stokes and anti-Stokes shift have very low 
intensities, noting that the cross section of the first is orders of magnitude lower than that 
of fluorescence.  
In order to increase this cross-section various methods were devised one of them 
involves using two laser beams, pump beam and Stokes beam. These two beams 
interfere and if this interference matches with the resonance frequency of a molecular 
bond the molecular bond vibration will be greatly enhanced. See Figure 1. This process 
can generate three different signals [2]: coherent anti-Stokes Raman scattering (CARS), 
stimulated Raman scattering (SRS) [3] and coherent Stokes Raman scattering (CRS) 
[3]. All of them have cross-sections orders of magnitude higher than spontaneous Raman 
scattering. 
Spectroscopy methods that apply Raman effect can then perform highly precise, 
label-free characterisation of samples. This together with the evolution of optical fibres 
permit the creation of novel, small scale probes that can enhance current in vivo 
endoscopic techniques for cancer detection. 
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Figure 1. Raman effect diagram, when a scattered photon is red-shifted (less energy) the interaction is named Stokes 
scattering. If it is blue-shifted an Anti-Stokes scatter has occurred, adapted from [3] 
 
Raman spectroscopy data is typically presented in wavenumbers, unit cm-1. The 
conversion from cm-1 to nm is simple and straightforward being it only a unit conversion 
as shown on the following formula. 
𝑤𝑎𝑣𝑒𝑛𝑢𝑚𝑏𝑒𝑟 (𝑐𝑚−1) =
107
𝑤𝑎𝑣𝑒𝑙𝑒𝑛𝑔𝑡ℎ (𝑛𝑚)
 (1) 
 
And therefore, Raman shifts, Δ𝑤, from a known wavelength, λ1, to a 
corresponding known second wavelength, λ2, are calculated as follows: 
 
Δ𝜔 =
𝜆1 − 𝜆2
𝜆2𝜆1
× 107  (2) 
 
For example, purposes a 785 nm excitation laser with a corresponding 1655 cm-
1 Raman shift gives a wavelength 902.21 nm for the Raman signal or a 909.09 nm laser 
with a 1000 nm Raman wavelength corresponds to a 1000 cm-1 Raman shift. Pure 
compounds with well-defined Raman peaks are used as calibration standards in Raman 
spectroscopy. The system collects the signal from such compounds and its result is 
compared with known data.  
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2.2 Applications in biomedical solutions 
 
2.2.1 Mammary tissue 
 
Several works were reviewed that analyse breast tissue with Raman 
spectroscopy, some of the works are not from human breast tissue and the reason is 
further explained in Chapter 4. As can be seen checking Table 1 the main ranges of 
analysis are the 800 – 1800 cm-1 (fingerprint zone) and 2800 – 3350 cm-1 (dominated by 
lipids and water) zones. 
The Raman signal of these regions is constituted by a myriad of biomolecules, 
from lipids, proteins, carotenoids, amino acids and nucleic acids mostly. Some mineral 
material is identified when in the presence of calcifications. 
From the reviewed works some bands were deemed more important than others. 
Such bands include the 1657 cm-1 and 1442 cm-1 [4, 5] that are argued, trough empirical 
evidence, as peaks that can be used to distinguish between healthy and lesioned tissue. 
Other bands would be ones associated with amino acids [6 – 8], proteins [4, 6 – 12], 
nucleic acids [8, 9, 12], calcifications [13], collagen [4, 7, 12]. As spectra that is dominated 
by such peaks is deemed as lesioned tissue, either it being a benign tumour or a grade 
of malign tumour. There are reports of malignant tissue also having presence of 
interstitial water as shown by the 3311 cm-1 peak [6, 10, 14]. Such case might be due to 
cancer cells being largely composed of proteins that are hydrophilic [15]. 
In contrast normal tissue is dominated by lipids, has presence of carotenoids 
[6, 10, 14, 15] and has no calcifications on it. The peaks for carotenoids mentioned are 
at 1158 cm-1, 1161 cm-1, 1520 cm-1, 1527 cm-1 and 1558 cm-1. Another aspect of interest 
is that normal tissue Raman signal has lesser contribution of fluorescence than that of 
lesioned tissue, leading to a less intense signal overall. As title of example, Figure 2 
illustrates an example of expected Raman spectroscopy signal from normal tissue, 
malignant tissue and benign tissue, adapted from [13].  
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Figure 2. Example of collected spectra from normal breast tissue (a), malignant (b) and benign (c). Adapted from [13]. 
 
Table 1 has a roundup of the beforementioned reviewed literature on the topic of 
Raman spectroscopy in mammary tissue. On the first column is the work reference 
number, second column has the peaks studied on same work and the third column has 
all the biomarkers determined on the article. Important bands present would be ones 
centred near 1440 cm-1 and 1660 cm-1 for being empirical evidence of tumoral tissue [4]; 
bands centred near known carotenoids peaks: 1158, 1520, 1527; peaks that are 
enhanced in malignant tissue [11]: 1545, 1585, 1605 and amino acid peaks such has: 
757 cm-1, 829 cm-1, 853 cm-1, 856 cm-1, 936 cm-1, 1002 cm-1, 1004 cm-1, 1026 cm-1, 
1045 cm-1, 1153 cm-1, 1156 cm-1, 1182 cm-1, 1208 cm-1, 1515 cm-1, 1549 cm-1, 1585 cm-
1, 1610 cm-1
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Table 1. Reviewed literature of Raman spectroscopy of mammary tissue 
Reference 
Important peaks/ bands 
(cm-1) 
Markers 
 
 
[4] 
 
 
1004, 1262, 1442, 1452, 1657, 
1660 
 
Amide I, Amide III, 
Phenylalanine, Proline, 
Hydroxyproline, 
Collagen, Lipids 
 
[6] 
 
1400 – 3000 
2800 – 3000 
1558 
3311 
 
 
Fatty acids, Proteins, 
Amino acids, 
Carotenoids, Water 
 
 
[7] 
 
728, 757, 782, 829, 853, 
1003, 1045, 1096, 1300, 
1442, 1460, 1549, 1575, 
1656, 1665, 1744 
1662 – 1664, 1739 – 1745, 
1759 – 1762 
 
 
Amide I, Tryptophan, 
Tyrosine, Taurine, 
Lipids, Ester, 
Phenylalanine, 
Proteins, Cholesterol 
[8] 
 
856, 936, 1002, 1004, 
1026, 1028, 1153, 1156, 
1208, 1448, 1515, 1585, 
1610, 1662, 800 – 985, 
1120 – 1690, 1200 – 1295 
 
 
Amide I, Amino acids, 
Lipids, Proteins Nucleic 
acids, Amide III 
 
 
 
 
[9] 
 
 
 
1260, 1442, 1662, 
800 – 960, 1080 – 1400, 
2700 – 3500 
 
Amide I, Collagen, 
Lipids, Phospholipids, 
Proteins, 
Acyglycerides, Amide 
II, Amino acids, Acyl 
chains, Cholesterol, 
Nucleic acids 
 
 
 
 
[10] 
 
 
558, 842, 972, 977, 1004, 
1098, 1116, 1158, 1240, 
1269, 1444, 1518, 1560, 
1660, 1740, 1750, 2854, 
2888, 2926, 2940, 3009, 
3311 
 
 
 
Carotenoids, Fatty 
acids, Lipids, Water, 
Proteins 
 
 
 
[11] 
 
750, 821, 1004, 1080, 
1087, 1156, 1172, 1223, 
1262, 1306, 1318, 1358, 
1378, 1441, 1453, 1460, 
1521, 1545, 1550, 1585, 
1589, 1605, 1656, 1663, 
1746, 2727, 2854, 2935, 
1330 – 1380 
 
 
 
 
Amide I, Amide II, 
Amide III, Lipids,  
Proteins 
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[12] 
 
 
788, 850, 1070, 1098, 
1267, 1301,1450, 1660 
 
 
 
 
 
Collagen, Lipids, 
Nucleic acids 
 
 
[13] 
 
1440, 1445, 1450, 1650, 
1657, 1746, 600 – 980, 
1140 – 1390, 1390 – 1510, 
2680 – 3100 
 
 
Phospholipids, 
Carotenoids, 
Acyglycerides, Amide I, 
Amide II, Amide III 
 
 
[14] 
 
2800 – 3000 
1158, 1161, 1520, 1527, 3311 
 
 
Water, Lipids, 
Carotenoids 
 
 
[15] 
 
1000 – 1600 
 
Carotenoids 
 
 
 
 
 
2.2.2 Digestive Tract 
 
As can be seen at the Appendix, Raman endoscopic systems were already 
developed for clinical use. There are several research works that apply Raman 
endoscopy to ex vivo and in vivo cancer detection [16-28]. Since endoscopy requires the 
insertion of a probe it can only be performed in human cavities like the digestive tract.  
As per analysis of the works there are key aspects that are worth of noting. The 
main markers in the Raman signal are peaks of biomolecules and cells (nucleic acids, 
proteins, lipids, collagen, glycogen, blood and others). Due to this, the range of acquired 
signals mainly goes from 800 cm-1 to 1800 cm-1 using near infrared Raman spectroscopy 
(NIR-RS). But, there are also studies using high wavenumber Raman spectroscopy (HW-
RS) for up to 3700 cm-1  [19, 23, 25] that collect Raman signal from water content in the 
tissues, note that the 1800 – 2800 cm-1 range provides no relevant information [33]. 
Classification tools such as linear discriminant analysis (LDA) and principal component 
analysis (PCA) are often used [16, 18-21, 24, 26, 27]. Also, remarks are made in main 
suspects that may help in differentiating normal tissue from cancerous tissue from 
abnormal nuclear activities such as: decrease in lipids presence in malignant ulcerous 
lesions [16]; bandwidth broadening at 1665 cm-1 and red shift around 1445 cm-1 for 
cancer tissue [17]; difference in peak intensity between cancer and normal tissue, with 
signal (in cm-1) from cancer tissue being higher in the 1070, 1323, 1345, 1576, 1588, 
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1467, 1618, 1662 and 1685 peaks [20, 26] and lower in the 855, 1019, 1065 and 1745 
[20, 26]; an inversion in spectral intensity centred at 1200 cm-1 is verified [26] and at 
1230 cm-1 [18]. An example of Raman signal, from digestive tract, is illustrated in Figure 
3. 
 
Figure 3. Raman spectra from normal stomach tissue and malignant and benign ulcers, adapted from [16]. 
 
 
In Table 2 a roundup of key aspects from digestive tract reviewed literature is 
presented. In a similar fashion as Table 1, the first column is the reference number of 
the article, second column has the location studied in that work, third column has the 
studied malignancy, the fourth column has the peaks found and for last the fifth column 
has all the biomolecules that correspond to the found peaks. Raman peaks that might 
prove of relevance would have to be ones associated with proteins and amino acids 
(especially if linked to collagen presence), such as:  855 cm-1, 1588 cm-1, 1467 cm-1, 
1662 cm-1, 1685 cm-1, and nucleic acids with peaks being: 1323 cm-1, 1345 cm-1. Also, 
peaks centred near 1440 cm-1 and 1660 cm-1 with them being empirical evidence of 
neoplasms [4].  
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Table 2. Collection of biomedical applications of Raman endoscopy for cancer detection in the digestive tract. 
Ref. Location 
Malignancy 
 
Important peaks/ bands 
(cm-1) 
Markers 
 
 
[16] 
 
 
Stomach 
 
 
Malignant and ulcerous 
lesions 
 
800–900 
1000–1100 1245–1335 1440–1450 
1500–1800 
 
Proteins, DNA, 
Lipids and 
Blood 
 
 
 
[17] 
 
Stomach 
 
Epithelial neoplasia 
 
1445 and 1655 
 
Nucleic acid, 
Phospholipids 
and Histones 
 
 
[18] 
 
Stomach 
 
 
Gastric adenomatous 
polyp 
Adenocarcinoma 
 
 
853, 936, 1003, 1032, 1174, 1208, 
1323, 1335, 1450, 1640, 1655, 1675 
 
Proteins, 
Lipids, 
Carbohydrates 
and Nucleic 
acids 
 
 
 
[19] 
 
 
Stomach 
 
 
Dysplasia 
Adenocarcinoma 
 
853, 1004, 1078, 1210, 1265, 1302, 
1335, 1445, 
1618, 1655, 1745, 2850, 2885, 2940, 
3250, 3300 
 
 
Proteins, 
Nucleic acids, 
Lipids and 
Water 
 
 
 
[20] 
 
 
Oesophagus 
 
 
Oesophageal cancer 
 
 
875, 936, 1004, 1078, 1265, 1302, 
1335, 1445, 1618, 1655, 1745 
 
DNA, Histones, 
Triolein, 
Collagen and 
Glycogen 
 
 
 
[21] 
 
 
 
Oesophagus 
 
 
 
Barret's oesophagus 
Neoplastic tissue 
 
 
 
487, 498, 686, 863, 933, 937, 1128, 
1360, 1571 
 
 
Glycogen, 
Nucleic acids 
and Proteins 
 
 
 
[22] 
 
 
Oesophagus 
 
 
 
 
 
Barret's oesophagus 
 
 
1004, 1335, 1576, 1655 
 
Phenylalanine, 
Proteins and 
DNA 
[23] Cervix Cervical dysplasia 
854, 937, 1001, 1095, 1253, 1313, 
1445, 1654, 2946, 3400 
 
Proteins, 
Lipids, 
Glycogen, 
Nucleic Acids 
and Water 
 
 
 
 
[24] 
 
 
 
Colon 
 
 
 
Ulcerative colitis 
 
 
 
610, 755, 896, 1044,1079,1081,1098, 
1102, 1155, 1246, 1256, 1262, 1314, 
1331, 1386, 1613 
 
Proteins, 
Lipids, Nucleic 
acids, 
Cholesterol, 
Phospholipids 
and Collagen 
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[25] Colon 
 
Adenocarcinoma 
Tubular adenomas 
Hyperplastic polyps 
 
 
1003, 1263, 1275, 1318, 1448, 1467, 
1582, 1634, 1657, 2850, 2930 
 
 
Phenylalanine, 
Amide III, 
Amide I, 
Proteins and 
Lipids 
 
[26] Colon Adenocarcinoma 800-1800 
 
Nucleic acids 
Proteins and 
Lipids 
 
[28] Oesophagus Barret’s oesophagus 
 
490, 492, 574, 638, 731, 771, 782, 
885, 933, 937, 1018, 1086, 1021, 
1095, 1110, 1128, 1334, 1360, 1511, 
1621 
  
 
Glycogen, 
Nucleic acids 
and Proteins 
 
 
2.2.3 Review of other biological samples 
 
Raman spectroscopy is a versatile technique not being limited to only analyse 
digestive tract and mammary tissues. On this point a brief overview of other tissue 
applications are presented.  
Larsson and Hellgren [29] using 488 nm light studied samples of blood plasma. 
A result they uncovered was the existence of differences in carotenoid spectral regions 
between patients with cancer and without. Verma et al., [30] would later confirm this 
finding.  
Differences between spectra of calcifications from both coronary artery and aortic 
valve where studied carried out by Clarke et al. [31] using 514.5 nm excitation light. 
Differences where suggested to stem from different structures and organizations of 
mineralized deposits. Carotenoids where also identified in atherosclerotic lesions; the 
514.5 nm light coincides with the absorption region of carotenoids resulting in more 
intensity from these modes [32]. 
Spectra of malignant lesions in the gynaecological tract, namely: ovarian, 
cervical, uterine and endometrial tissues appear to be similar between them from the 
work of Alfano et al., [33]. Besides peaks due to amide (1650 cm-1, 1445 cm-1, 1240 cm-
1, 1260 cm-1) some pathologies showed a peak of tryptophan near 1330 cm-1. 
A ratio of grey matter to white matter was developed by Ozaki et al., [34] this was 
done studying spectra from rat brain samples. The bands from proteins and 
phospholipids were consistent with chemical composition of the samples and as such 
the ratios of these peaks, lipids and proteins, was used to evaluate the ratio of grey to 
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white matter. Differences between human brain healthy tissue and brain tumours was 
analysed by Mizuno et al., [35]. A difference was found in glioma grade III that had much 
prevalent bands in 1130 cm-1 and 856 cm-1 comparing to normal tissue. These bands 
are due to an increase in trans lipids and polysaccharides respectively. Also, a tumour 
of the arachnoidal choroid plexus, central neurocytoma, exhibited a characteristic band 
at 960 cm-1 that indicated the presence of hydroxyapatite.  
Bladder tissue was studied by Feld et al. [36], the differences between normal 
and lesioned tissue appear similar to the differences in normal and lesioned tissue of 
colon tissue, so similar tissue differences as the ones presented in point 2.2.2.  The main 
differences are that there is an increase in the nucleic acid content with an associated 
decrease in lipid presence, all this in lesioned tissue when comparing to normal tissue.  
Manoharan et al., [5] analysed a sarcoma of fatty tissues, liposarcoma, using an 
830 nm laser. Malignant tissue presented bands associated to carotenoids (1156 cm-1 
and 1528 cm-1) and the 1442 cm-1 and 1666 cm-1 bands suffered an alteration due to 
CH2 bending modes and C=C stretching. 
Chicken bone was compared to synthetic hydroxyapatite and human tooth 
samples were studied by Nie et al., [37]. Chicken bone presented bands due to apatite 
at 451 cm-1, 960 cm-1 and 1072 cm-1. Collagen spectrum, namely bands of proline and 
hydroxy proline were also present. Tooth also presented apatite peaks when sampling 
the enamel, closely to 96.5% inorganic material [4], at 591 cm-1, 961 cm-1, and 1071 cm-
1. Dentine and root spectra showed that proteins modes are dominant, which is 
consistent to an increased protein content (an increase of circa 25% [4]). 
 
2.3 Closing Remarks 
 
Raman spectroscopy enables fast, label free discrimination of the molecular 
components in the sample analysed. Trough analysis of such components a judgement 
can be done regarding the tissue being sampled.  
Of interest is the utility for cancer tracking, as seen in referenced works (see 
section 2.2), where fast acquisition times are doable with also high precision in discerning 
between benign and malignant tissues. 
In conjunction with the latest optical fibres (see Appendix), in vivo Raman 
spectroscopy sampling of biological tissues is possible. Thus, permitting the addition of 
a Raman spectroscopy probe to current endoscopy techniques. 
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With such, the proposal of this dissertation is the analysis of both healthy and 
lesioned tissue in order to assert the conclusion done through the reviewed work and to 
try to give more insight regarding the molecular composition of biological tissue, 
especially malignant one. 
To realise such, the most important albeit general aspects taken for the Raman 
spectroscopy is the laser wavelength used. With that in mind, 785 nm excitation 
wavelength appears to be a suitable wavelength as seen in the works [16, 20, 22, 27 ]. 
The Raman signal collected would be divided into two bands, being the first from 
800-1200cm-1 and the second from 1200 - 1800 cm-1 due to signal inversion around the 
wavenumber. The possible fingerprint peaks to look for would be (in cm-1): 1004, 1335, 
1445, 1618 and 1655 for being recurring peaks across multiple works.
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Chapter 3 – Raman spectroscopy in 
mammary tissue 
 
3.1 Introduction 
 
In this chapter, the results of near infra-red Raman spectroscopy (NIR-RS) 
utilized to probe samples from a household cat mammary tissue are presented. The 
structure is as follows, first the results of what is determined as being healthy tissue is 
presented. Afterwards differing spectra is presented. After all results are shown 
comparisons between the different spectra is done. At last the concept of “comparative 
oncology” is further explored. A compilation of the determined results as a takeaway 
message gives closure to this chapter. 
3.2 Instrumentation 
 
 The instrument used is an inVia Qontor Renishaw confocal Raman spectrometer. 
It has 250 mm of focal length, spectral range from 200 – 1064 nm with an efficiency of 
30 percent. It is based in lenses directly coupled to a vertical microscope and with a high 
sensitivity, in the range of 200 – 1064 nm, Peltier cooled, at -70 ºC, CCD with 
1024 x 256 pixels. It is also equipped with filters for three excitation lasers: 532 nm, 
633 nm and 785 nm with spectral range of 100 – 4000 cm-1. It allows both Stokes and 
Anti-Stokes Raman spectroscopy with < 10 cm-1 starting from the 532 nm laser line. It 
also possesses three high efficiency diffraction gratings: 1200 lines/mm, 1800 lines/mm 
and 2400 lines/mm with high spectral resolution < 2 cm-1 in all spectral range. The setup 
photograph and schematic can both be seen in Figure 4. 
 
Figure 4. Experimental setup utilised for present work, in first plane the inVia Qontor Renishaw confocal Raman 
spectrometer. In the background the set of lasers available: 532 nm, 633 nm and 785 nm. 
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3.3 Experimental data 
 
All data collected is from cat mammary tissue samples that were provided by the 
Veterinary Hospital from the University of Évora. It was collected using near infra-red 
Raman spectroscopy (NIR-RS), at 785 nm, 0.005 mW and a 50x magnification lens. 
Acquisition times ranged from 1 second to 10 seconds. Many samples were analysed, 
from which the presented ones in this work were chosen as an example, note that all 
samples were fixed in formaldehyde. Samples were analysed in multiple far apart regions 
and differing structures. . Therefore, adding to the acquired spectra some microscope 
images were also taken (on the scale of a few micrometres to a few millimetres). In the 
scale of micrometres, the surface appearance is somewhat homogeneous albeit rough. 
Small darker spots appear, albeit not often, and were sampled along with some dark 
patches and other elongated structures. All these descriptions can be verified on images 
presented further along the text. Data is presented in the form of graphs and mappings; 
mappings are  distributions of the of a chosen peak  juxtaposed over a white light image 
of the sample. Peaks chosen are possible fingerprint peaks. For each graph and 
mapping a brief description and analysis is done comparing the data collected with the 
referenced literature. Shown spectra are exemplary of the rest of acquired spectra for 
that sample or for that type of tissue spectra unless said otherwise. 
An empirical way of determining between normal and abnormal breast tissue is 
reported in Manoharan et al. [4, 5]. It consists of two points, one being a shift on the 
1440 cm-1 mode, in normal tissue, towards 1450 cm-1 in abnormal one, and the second 
being a peak broadening and shift from 1650 cm-1 to 1667 cm-1 also from normal to 
abnormal tissue. Another aspect is that normal tissue presents much less fluorescence, 
therefore less intensity, when comparing to abnormal tissue [4, 5].  
Another aspect to consider is that spectra from healthy tissue is dominated by 
lipids, fatty acids and triglycerides [4-15] and that it resembles the spectra from oleic acid 
[4, 10, 19]. While the spectra from cancerous tissue is mainly dominated by proteins [4, 
5, 10, 13] even being compared with pork muscle tissue [10]. 
Also reported is a higher presence of carotenoids, anti-oxidant agents, in healthy 
tissue [6, 10, 13, 14, 15], carotenoids appear inside unsaturated fatty acids and 
triglycerides [10]. Cancerous tissue shows no presence of carotenoids in all works 
barring Manoharan et al., [4, 5] where contradicting results appear in liposarcoma 
(carotenoids on liposarcoma) [5] versus carcinoma and fibrosis tissues in breast samples 
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(that present a decrease in carotenoids comparing to healthy breast samples) [4]. A 
higher presence of collagen in cancerous tissue is also noted, as also certified with 
histopathology studies [4].  
The beforementioned points will be used to help classify the different spectra that 
will be presented below.  
Also note that the names given to tissue and the samples name are not related. 
From the various samples given only some gave good results and when a letter is used 
to name a sample it refers to being from the same sample but a different region.  
 
3.3.1 Healthy Tissue 
 
This type of tissue spectra which was attributed as being from healthy tissue was 
found in all four samples. The determined peaks can be seen in Figure 5. The average 
was calculated using 29 spectra with 1 second acquisition time each, ~1.63 mW of laser 
power at 785 nm.  
 
Figure 5. Healthy tissue spectrum obtained through averaging 29 acquisitions.  
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The origin of the determined peaks present in Figure 5 are as follows: 
• 868 cm-1 proline. 
• 968 cm-1 C-C stretching of lipids. 
• 1064 cm-1 skeletal C-C stretch lipids 
• 1083 cm-1 C-N stretching mode of proteins (and lipid mode to lesser degree). 
• 1121 cm-1 C–C stretch (breast lipid). 
• 1264 cm-1 =C–H in plane bending (lipid). 
• 1300 cm-1 C-H (CH2) bend, vibrational modes of lipids. 
• 1440 cm-1 vibrational modes of lipids. 
• 1455 cm-1 no reference found. 
• 1656 cm-1 amide I (C=O stretching mode of proteins, a-helix conformation)/C=C                                      
lipid stretch. 
• 1742 cm-1 C=O stretch (lipid), vibrational modes of lipids. 
 
As mentioned before, the empirical findings, the presence of the 1440 cm-1 and 
1656 cm-1 peaks (the maximum recorded difference was by 4 cm-1) raises the flag as this 
spectrum belonging to healthy tissue. Checking the peaks is easy to notice that all of 
them can be attributed as being originated from lipids with some, but few, protein 
contributions in-between which is another pointer towards that belief. Denote that both 
carotenoids and collagen are absent from these spectra.  
Figure 6 presents  comparisons between  spectra from different samples. Note that 
these spectra were acquired with a longer acquisition time than the ones shown on 
Figure 5,  namely of 10 seconds, while maintaining the rest of the parameters.  
All peaks present in Figure 6  can be seen  in Figure 5, albeit the 1083 cm-1 and 
1455 cm-1 peaks are somewhat “hidden” due to present noise. Some key aspects to take 
would be that the peak centred around 1440 cm-1 (lipid peak) is the highest peak present 
in all spectra. And the 1657 cm-1 peak is usually below half of the 1440 cm-1 peak.  
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Figure 6. Comparison between two distinct acquirement positions from Sample 2 and spectrum from Sample 4.  
 
Table 3 shows the fraction between proteins (amide I, 1660 cm-1) and lipids 
(1300 cm-1), it was calculated by doing the fraction between the areas of the 
corresponding peaks. The idea behind it is that, as said in point 2.2.1, mammary tumoral 
tissue presents a higher concentration of proteins/amino acids and a degradation of lipids 
[4 – 12], thus the evaluation of such ratios might help at discerning between tissues.  
 
Table 3. Peak area fractions between proteins and lipids contributions from Sample 2 and Sample 4. 
 
1660/1120 
(Amide 
I/Glucose) 
1300/1120 
(Lipid/Glucose) 
1660/1300 
(Amide I/Lipid) 
Sample 2 A 
1.346 
 
1.722 
 
0.677 
 
Sample 2 B  
1.475 
 
2.012 
 
0.733 
 
Sample 4 1.549 2.288 0.781 
 
On this table it is shown that the proportion of amide I is less than the lipid amount. 
Joining this information with the one from the previous paragraph it can be argued that 
the tissue analysed is healthy tissue. Also by comparing the spectra from Figure 6 and 
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the ratios of Table 3 it might be safe to assume that albeit from different samples it is the 
same tissue that is being analysed.   
 
3.3.2 Lesion 1 
 
The following picture, Figure 7, is a microscope image taken with 50x 
magnification of the “patchy” tissue of Sample 1 that presented spectra dubbed as 
Lesion 1. 
 
 
Figure 7. Microscope image taken with 50x magnification of Sample 1 tissue that gave spectra dubbed as Lesion 1. 
 
In Figure 8, the average spectrum shown is made out of spectra only found on 
Sample 1.  The average was calculated using 28 spectra each with 1 second of 
acquisition time, ~1.63 mW of laser power at 785 nm. The corresponding tissue to this 
type of spectra was named Lesion 1.  
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Figure 8. Lesion 1 average spectrum obtained by averaging 28 spectra. 
The following are the determined peaks on Figure 8 spectrum: 
• 754 cm-1 symmetric breathing of tryptophan (amino acid). 
• 797 cm-1 no reference found. 
• 820 cm-1 O–P–O stretch (DNA). 
• 975 cm-1 no reference found. 
• 1002 cm-1 symmetric ring breathing mode of phenylalanine (amino acid), 
vibrational modes of proteins. 
• 1124 cm-1 C–C stretching mode of lipids/protein, C–N stretch, glucose. 
• 1147 cm-1 no reference found. 
• 1180 cm-1 cytosine, guanine, adenine (nucleic acids). 
• 1190 cm-1 C–C6H5 phenylalanine, tryptophan (amino acids). 
• 1217 cm-1 amide III: b-sheet. 
• 1240 cm-1 amide III: collagen (CH2 wag, C–N stretch)/ pyrimidine bases (C, T). 
• 1302 cm-1 C-H (CH2) bend, lipids, CH2 deformation (lipid)/adenine, cytosine. 
• 1343 cm-1 CH3CH2 wagging mode of collagen. 
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• 1376 cm-1 nucleic acids. 
• 1551 cm-1 vibrational modes of proteins. 
• 1572 cm-1 pyrimidine ring (nucleic acids) and haemoprotein. 
• 1586 cm-1 no reference found. 
• 1623 cm-1 no reference found. 
 
 
With these results it can be noticed a rich presence in proteins, followed by nucleic 
acids and collagen, also there is a lack of glucose bands that were present in the two 
previous tissues. As mentioned before on section 2.2.1, spectra dominated by proteins 
[4, 6 – 12], nucleic acids [8, 9, 12] and collagen [4, 7, 12] is deemed as lesioned tissue, 
it might either be benign or a malign tumour. The high presence of nucleic acids might 
be explained the same way as having a higher content of proteins present in cancerous 
tissue. It is likely due to a higher density of cells present on the analysed area. 
On Figure 9, three spectra from distinct positions, distinct not only between each other 
but also from the spectra used on the average in Figure 8, is shown. These spectra 
where acquired using an acquisition time of 10 seconds, maintaining the other 
parameters, same as the spectra on Figure 6.  
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Figure 9. Comparison between spectra acquired in three distinct acquirement positions on Sample 1. 
 
Since the spectra above where not averaged they appear noisier. The highest 
present peaks (1212 cm-1, 1245 cm-1, 1370 cm-1, 1545 cm-1, 1568 cm-1) are all due to 
either proteins or nucleic acids with the lipid contributions being only from 1309 cm-1. The 
1120 cm-1 peak can originate from both proteins, lipids and glucose (a simple sugar). 
Peaks can still be cross referenced with the above ones albeit the shift. 
Table 4 presents the calculated fractions between contributions from proteins 
(1545 cm-1), lipids (1309 cm-1) and nucleic acids (1374 cm-1). It can be inferred that both 
proteins and nucleic acids are the dominant species on this type of tissue spectra, both 
being more intense than glucose and lipids. This further denotes the tissue as having a 
high presence of cells that are not adipose cells. Which helps to corroborate the idea 
that the tissue in question, Lesion 1, is not healthy tissue. 
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Table 4. Peak area fractions between proteins, glycose, and lipids belonging to Sample 1. 
 
1545/1120 
(Proteins/Glucose) 
1545/1309 
(Proteins/Lipids) 
1545/1374 
(Proteins/Nucleic acids)  
Sample 
1 A 
1.079 
 
1.617 
 
0.894 
 
Sample 
1 B 
1.045 
 
1.687 
 
0.814 
 
Sample 
1 C 
1.064 
 
1.819 
 
0.834 
 
3.3.3 Lesion 2 
 
Depicted in Figure 10 is the average spectra calculated by averaging 23 spectra, 
each with 1 second of acquisition time, ~1.63 mW of laser power at 785 nm. These 
spectra were only found in one sample, Sample 3 and named as Lesion 2. The peaks 
origins are enumerated right after Figure 10.  
 
Figure 10. Lesion 2 spectra obtained from averaging 23 spectra. 
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The peaks origins were determined as to be: 
• 748 cm-1 no reference found. 
• 781 cm-1 cytosine, uracil ring breathing (nucleotide). 
• 833 cm-1 out of plane ring breathing tyrosine (amino acid), O–P–O stretch DNA. 
• 850 cm-1 ring breathing mode of tyrosine and C–C stretch of proline (amino acid) 
ring. 
• 954 cm-1 hydroxyapatite a type II calcification, carotenoid, cholesterol.  
• 1009 cm-1 phenylalanine, CH3 rocking coupled with C-C stretching of carotenoids. 
• 1087 cm-1 C–C stretch, O–P–O– stretch. 
• 1109 cm-1 no reference found. 
• 1145 cm-1 no reference found. 
• 1196 cm-1 no reference found. 
• 1218 cm-1 amide III: b-sheet. 
• 1309 cm-1 CH2 deformation (lipid), adenine, cytosine. 
• 1343 cm-1 CH3CH2 wagging mode of collagen. 
• 1371 cm-1 guanine, TRP (protein), porphyrins, lipids. 
• 1430 cm-1 CH2 deformation (lipid). 
• 1453 cm-1 CH2 bending mode of proteins, CH2(overlapping asymmetric CH3 
bending & CH2 scissoring (is associated with elastin, collagen and 
phospholipids). 
• 1531 cm-1 vibrational modes of proteins. 
• 1553 cm-1 vibrational modes of proteins. 
• 1591 cm-1 no reference found. 
• 1611 cm-1 C=C stretching mode of tyrosine and tryptophan. 
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This spectra presents various peak contributions from proteins, amino acids, nucleic 
acids and collagen same as the spectra from Lesion 1, presented before. Differences 
between them come in lesser presence of lipids and a presence of hydroxyapatite, a 
mineral form of calcium phosphate with an apatite structure, which is determined as 
being a type II calcification [13].  Type II calcifications are the more frequent ones and 
albeit not always they are the result of malignancy [38]. There are also peaks centred at 
1309 cm-1 and 1453 cm-1, with the latter being  a possible shift of the 1440 cm-1 peak 
which was referenced before, section 2.2.1 and section 3.3,  as an empirical evidence of 
a neoplasm [4]. 
 
Depicted in Figure 11 are three spectra chosen from many as an example, they were 
all acquired in different locations from each other, different from the locations of spectra 
used on Figure 10, and all with an acquisition time of 10 seconds, keeping the rest of 
parameters. The left-most peak on Figure 11, namely 950 cm-1, is confirmation of 
presence of type II calcifications.  
 
Figure 11. Comparison between three distinct acquirement positions on Sample 3, all with the Lesion 2 spectra. 
In Table 5, the ratios between lipids (1448 cm-1), collagen (1335 cm-1), proteins 
(1524 cm-1) and calcification (950 cm-1) contributions are represented. Their data was 
calculated from the spectra shown is Figure 11. It can be inferred that proteins (1524 cm-
1) are the main contributor followed right after by collagen (1335 cm-1) then lipids 
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(1448 cm-1). With such major contribution from proteins [4, 6 – 12], collagen [4, 7, 12] 
with also the presence of a type II calcification [13, 38] it cements the idea that this tissue, 
Lesion 2, is malignant in nature.  
 
Table 5. Peak area fractions from peaks belonging to Sample 3. 
 
1448/1524 
(Lipid/Protein) 
1335/1448 
(Collagen/Lipid) 
1335/1524 
(Collagen/Protein) 
950/1335 
(Calcification/Collagen) 
Sample 3 A 0.438 
 
1.620 
 
0.709 
 
0.439 
Sample 3 B 
 
0.459 1.502 0.689 0.436 
Sample 3 C 0.457 1.494 0.683 0.433 
 
3.3.4 Lesion 3 
 
In Figure 12, a microscope image that was taken with 50x magnification is presented. 
Multiple samples presented this type of spectra and this image serves as an example on 
what the tissue that has this type of spectra may look like. The morphology of the tissue 
ranged from a filiform appearance to a scar-like one as can be seen on Figure 12.  
 
 
Figure 12. Microscope images of the “filiform appearance” structure, 10x magnification, and the “scar-like” one, with 50x 
magnification. 
 
On Figure 13, an average spectra is shown. This spectra was done by averaging 38 
spectra, where each was acquired in different locations from multiple samples and with 
1 second of acquisition time, ~1.63 mW laser power at 785 nm. This type of spectra was 
named Lesion 3, one peculiarity of it is a doublet appearing at 1575 cm-1  – 1585 cm-1.  
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Figure 13. Lesion 3 spectra, average of 38 spectra acquired from different positions across multiple samples. 
 
The sampled peaks, taken from the average spectra in Figure 13, are as follows: 
• 759 cm-1 tryptophan. 
• 776 cm-1 C–C stretch of proline, hydroxyproline and tyrosine and v2 PO2 stretch 
of nucleic acids bands). 
• 863 cm-1 tyrosine, collagen. 
• 871 cm-1 proline. 
• 1017 cm-1 no reference found. 
• 1097 cm-1 O-P-O (stretching PO2 symmetric (Phosphate II)) of phosphodiesters. 
• 1149 cm-1 no reference found. 
• 1176 cm-1 C–H in-plane bending mode of tyrosine. 
• 1190 cm-1 C–C6H5 phenylalanine, tryptophan. 
• 1226 cm-1 Amide III: b-sheet.  
• 1249 cm-1 Amide III: collagen (CH2 wag, C–N stretch)/ pyrimidine bases (C, T). 
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• 1313 cm-1 CH3CH2 twisting mode of collagen, lipids. 
• 1366 cm-1 guanine, TRP (protein), porphyrins, lipids. 
• 1463 cm-1 no reference found. 
• 1483 cm-1 nucleic acid purine bases (guanine and adenine). 
• 1575 cm-1 pyrimidine ring (nucleic acids) and heme protein. 
• 1585 cm-1 no reference found. 
• 1623 cm-1 no reference found. 
• 1633 cm-1 C-O asymmetric stretching. Calcium oxalate dihydrate, type I 
calcification. 
• 1702 cm-1 no reference found. 
 
The results show a high presence of amino acids, proteins, collagen, nucleic 
acids, a calcification and of interest there is no peak that is purely associated with lipids. 
Other key notes that are extracted from this type of spectra is the following: as 
mentioned, there is a well-defined narrow band on the 1575 cm-1  – 1585 cm-1 range with 
two distinct peaks present, a doublet. There is a lack of the peak from glucose, that was 
present in healthy tissue and Lesion 1. The 1300 cm-1 and 1440 cm-1 peaks that were 
seen on previous shown spectra, healthy tissue, appear to be shifted to 1313 cm-1 and 
1460 cm-1 respectively and the latter might be empirical evidence of a neoplasm, as 
stated before. They are the only spectra with a peak centred at 1633 cm-1, which is a 
type I calcification. This type of calcifications are uncommon when compared to type II 
and are associated with benign processes [38].  
 
In Figure 14 a comparison between spectra acquired from three different 
acquisition locations, between two samples, is presented as an example, all were 
acquired with 10 seconds of acquisition time, keeping the same parameters of power 
and laser frequency. 
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Figure 14. Comparison between Lesion 3 spectra, two originating from Sample 2 and one from Sample 3. 
 
Table 6 presents fractions between the doublet (1585 cm-1/1575 cm-1) and type I 
calcification (1633 cm-1) with nucleic acids (1482 cm-1), their data was acquired from the 
spectra presented on Figure 14. From the fact the doublet ratio is quite  similar between 
different spectra it is likely that both peaks have the same species origin and might prove 
useful for further study.  
Due to having  a type I calcification [38], high contributions from proteins [4, 6 – 12] and 
presence of collagen [4, 7, 12] is safe to assume that Lesion 3 spectra is likely to 
represent a benign neoplasm.  
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Table 6. Peak area fractions between the doublet, type I calcification and nucleic acids from spectra presented in Figure 
14. 
 
1585/1575 
(-/Nucleic acids) 
1633/1482 
(Calcification/Nucleic acids) 
Sample 
2 A 
0.58141 
 
0.486328 
 
Sample 
2 B 
0.632379 
 
0.436333 
 
Sample 
3 
0.632834 
0.435595 
 
 
3.4 Comparisons between tissues 
 
Figure 15 presents a comparison between all four different spectra acquired 
across all samples. All spectra used to average were acquired with same conditions of 
laser power, ~1.63 mW, and acquisition time, 10 seconds.  
 
Figure 15. Comparison between the average spectra of all three Lesions and Healthy Tissue. 
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The first thing of note is as referenced before, healthy tissue has overall less 
fluorescence than tissue with lesions [4, 13]. Another way to differentiate healthy tissue 
spectra is that it presents well defined peaks centred at 1440 cm-1, 1656 cm-1 and 
1742 cm-1. 
Lesion 1 tissue spectra are the only ones with four well defined peaks in the 
1550 cm-1 – 1623 cm-1 region, and the 1551 cm-1, 1572 cm-1, 1586 cm-1 and 1623 cm-1 
peaks. Also presents the 1376 cm-1 peak. And while Lesion 3 also presents the 1572 cm-
1,1586 cm-1 (at 1575 cm-1 and 1585 cm-1 respectively) and 1623 cm-1 they are not near 
as intense. The only spectra not having a peak in the 1440 cm-1 – 1460 cm-1 range. 
Lesion 2 tissue spectra are the ones with three very narrow peaks in 748 cm-1, 
1343 cm-1 and 1531 cm-1. It is also the only one with a type I calcification peak (954 cm-1). 
Albeit Lesion 1 does also present the 1343 cm-1 peak it is not as narrow nor intense 
comparatively. As mentioned before Lesion 1 has a possible shift of the 1440 cm-1 peak 
towards 1453 cm-1 [4].   
Lesion 3 spectra presents narrow bands at 1575 cm-1 and 1585 cm-1 while also 
having a type I calcification present (in 1633 cm-1). The 1463 cm-1 peak is a possible shift 
of the 1440 cm-1 peak as previously written [4]. 
There appears also to be a shift of the 1300 cm-1 peak towards 1309 cm-1 in 
Lesion 2 and 1313 cm-1 in Lesion 3 that was not previously mentioned in the reviewed 
literature. And since both were tentatively classified as being a malign neoplasm and a 
benign one, respectively, this result might also be a major empirical evidence in helping 
to differentiate between neoplasms to add to previously mentioned before by 
Manoharan et al.  [4].  
There are several other peaks that can be observed on Figure 15 that are not 
discussed, namely: 748 cm-1 (Lesion 2), 797 cm-1 (Lesion 1), 975 cm-1 (Lesion 1), 
1017 cm-1 (Lesion 3), 1109 cm-1 (Lesion 2), 1175/1176 cm-1 (Lesions 1 and 3), 1196 cm-
1 (Lesion 2), 1226 cm-1 (Lesion 3), 1249 cm-1 (Lesion 3), 1463 cm-1 (Lesion 3), 
1585/1586 cm-1 (Lesions 1 and 3), 1591 cm-1 (Lesion 2), 1623 cm-1 (Lesions 1 and 3) 
and 1702 cm-1 (Lesion 3). The explanation is that no literature was found to determine 
the origin of those peaks.  
On Figure 16, are depicted two mappings that provide the peak intensity 
distribution comparing between healthy tissue and Lesion 3 tissue,  From the same 
sample. Albeit the peaks compared appear close,   it proves enough to trace zones that 
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closely approach the tissue morphology. Mappings are distributions of the of a chosen 
peak juxtaposed over a white light image of the sample. 
 
 
 
Figure 16. Two mappings, as example, with the over position of peaks from healthy tissue and Lesion 3 tissue. The over 
posed peak intensity distribution is respectively the 1445 cm-1 – 1464 cm-1 (top left) and 1300 cm-1 – 1311 cm-1 (bottom 
left) peaks. Right side is the spectra acquired on the point marked by the crosshair of the left side. 
 
At Table 6 the roundup of peaks that were found in the studied tissues and with 
known origins is presented along with the determined sources of each peak. 
 
Table 6. Compilation of peaks found in the sample’s analysis. 
Peak (cm-1) Origin Sample 
 
754 
 
symmetric breathing of tryptophan Lesion 1 
 
759 
 
Tryptophan Lesion 3 
776 
 
C–C (C–C stretch of proline, hydroxyproline and tyrosine and stretch of 
nucleic acids bands 
 
Lesion 3 
 
781 
 
cytosine, uracil ring breathing (nucleotide) Lesion 2 
 
820 
 
O–P–O stretch Lesion 1 
 
833 
 
out of plane ring breathing tyrosine (amino acid), O–P–O stretch DNA Lesion 2 
 
850 
 
ring breathing mode of tyrosine and C–C stretch of proline (amino acid) ring Lesion 2 
 
863 
 
tyrosine, collagen Lesion 3 
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868 – 871 
 
 
 
Proline 
 
 
Healthy 
Tissue 
Lesion 3 
 
954 
 
 
Hydroxyapatite (type II calcification), carotenoid, cholesterol 
 
Lesion 2 
 
968 
 
C-C stretching of lipids 
Healthy 
Tissue 
1002 
 
symmetric ring breathing mode of phenylalanine (amino acid), vibrational 
modes of proteins. 
 
Lesion 1 
 
1009 
 
 
phenylalanine, CH3 rocking coupled with C-C stretching of carotenoids 
 
Lesion 2 
1064 Skeletal C–C stretch lipids 
 
Healthy 
Tissue 
 
 
1083 
 
C–N stretching mode of proteins (and lipid mode to lesser degree) 
 
 
Healthy 
Tissue 
 
 
1087 
 
C–C stretch, O–P–O– stretch Lesion 2 
 
1097 
 
 
O-P-O (stretching PO2 symmetric (Phosphate II) of phosphodiesters 
 
Lesion 3 
1121 C–C stretch (breast lipid) 
 
Healthy 
Tissue 
 
1124 
 
C–C stretching mode of 
lipids/protein, C–N stretch, glucose 
 
Lesion 1 
 
1170 
 
C–H in-plane bending mode of tyrosine Lesion 1 
 
1180 
 
cytosine, guanine, adenine Lesion 1 
1190 C–C6H5 phenylalanine, tryptophan 
 
Lesion 1 
Lesion 3 
 
1217 - 1218 amide III: b-sheet 
 
Lesion 1 
Lesion 2 
 
 
1240 
amide III: collagen (CH2 wag, C–N stretch)/ pyrimidine bases (C, T) 
 
Lesion 1 
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1264 =C–H in plane bending (lipid) 
 
Healthy 
Tissue 
 
1300 C-H (CH2) bend, vibrational modes of lipids 
 
Healthy 
Tissue 
 
1302 C-H (CH2) bend, lipids, CH2 deformation (lipid)/adenine, cytosine 
 
Lesion 1 
 
1309 CH2 deformation (lipid), adenine, cytosine 
 
Lesion 2 
 
1313 CH3CH2 twisting mode of collagen, lipids 
 
Lesion 3 
 
1343 CH3CH2 wagging mode of collagen 
 
Lesion 1 
Lesion 2 
 
1366 guanine, TRP (protein), porphyrins, lipids 
 
Lesion 3 
 
1371 guanine, TRP (protein), porphyrins, lipids 
 
Lesion 2 
 
1376 nucleic acids 
 
Lesion 1 
 
1430 CH2 deformation (lipid) 
 
Lesion 2 
 
1440 Vibrational modes of lipids 
 
Healthy Tissue 
 
1453/1455 
 
CH2 bending mode of proteins, CH2(overlapping asymmetric CH3 
bending & CH2 scissoring (is associated with elastin, collagen and 
phospholipids) 
 
 
Lesion 2 
Healthy Tissue 
 
1483 nucleic acid purine bases (guanine and adenine) 
 
Lesion 3 
 
1531 vibrational modes of proteins 
 
Lesion 2 
 
1551 vibrational modes of proteins 
 
Lesion 1 
 
1572-1575 pyrimidine ring (nucleic acids) and haemoprotein 
 
Lesion 1 
Lesion 3 
 
1611 C=C stretching mode of tyrosine and tryptophan 
 
Lesion 2 
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1633 
C-O asymmetric stretching. Calcium oxalate dihydrate, type I 
calcification 
 
 
Lesion 3 
 
 
1656 
Amide I (C=O stretching mode of proteins, a-helix conformation)/C=C 
lipid stretch 
 
Healthy Tissue 
 
1742 
C=O stretch (lipid), 
vibrational modes of lipids 
 
Healthy Tissue 
 
 
3.5 Comparative oncology 
 
As said before, some similarities between cancerous tumours found in humans 
and those found in animals led to the concept of “comparative oncology”, thus permitting 
a cross evolution of cancer research [14]. Comparative oncology studies cancer 
pathogenesis and new treatment options for occurring cancers in animals. Majority of 
focus is put on the domestic dog but more species like cat, horse and ferret are of interest 
[39]. It has the advantage of bringing more data to cancer research since natural 
occurring cancers in animals can be translated to humans. If the animal in study presents 
a good or representative model of cancer evolution that simulates human pathological 
conditions, then that animal is a good candidate to study [40]. With that, pet animal 
cancers are comparable both in size and evolution with human cancers [41]. Another 
advantage of using animals, especially companion animals such as dogs or cats, is that 
they cohabit with humans. Sharing the living environment and as likely exposed to 
carcinogenesis as humans [41], one disadvantage in using such animals so far is the 
lack of specific tools that are already deployed to human research [41]. Mammary tumour 
incidence is around 34.5% in cats [42], thus, the focus of this work on the domestic cat, 
since it is easier to get access to samples and results still hold human clinical interest.  
3.6 Conclusion 
 
The results obtained where mostly in check with the reviewed literature. All 
spectra showed presence of biomolecules with enough difference between tissues to 
draw a line that differentiates them. In other words it means that healthy tissue showed 
a prevalence of lipids and lower fluorescence contrasting with the dubbed lesioned 
tissue. On the other side, lesioned tissue  presented more protein content, increase in 
collagen, more nucleic acids contributions, amino acids, an increased presence of 
collagen (with presence of proline and hydroxy proline in some spectra). Both types of 
calcifications (calcium oxalate dihydrate and hydroxyapatite) appear in two distinct 
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tissues. Of note is that, differing from the literature, carotenoids where not prevalent, 
actually it was not even found in what was determined as healthy tissue and was a minor 
presence in one of the lesioned tissues. One explanation might be due to how the 
samples were preserved as they were fixed in formaldehyde.  
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Chapter 4 – Conclusion and future work 
 
4.1 Conclusion and future work 
 
 In conclusion, the work done was a good step to give insight in Raman 
spectroscopy techniques and also data analysis methods. Not only that, the results in 
general were in line with the overviewed literature while also providing more information 
when talking about specific regions of the spectrum.  
Out of the four samples, four types of differing tissue spectra were studied. Tissue 
determined as being healthy tissue provided spectra dominated by lipids while also 
having less fluorescence than other tissues spectra. Tissue dubbed as Lesion 1 
presented a major presence of proteins, nucleic acids and collagen. Such contributions 
point to this tissue having a neoplastic nature while not confirming if either a benign or 
malign neoplasm. Lesion 2 samples showed a high presence of proteins, amino acids, 
nucleic acids and collagen. Similar to Lesion 1 in that regard. The major differing factor 
from all other tissues is the presence of hydroxyapatite, a type II calcification. This type 
of calcifications is more frequent than type I and while not always they are mostly the 
result of malignancy, making then Lesion 2 a malignant lesion. For last, Lesion 3 has a 
major contribution from amino acids associated with collagen and has a presence of 
calcium oxalate dihydrate, a type I calcification. As mentioned before, these are less 
frequent than type II and are associated with benign processes. 
In sum, differing from lesioned tissue, healthy tissue presented a higher 
contribution from lipids to the spectra while also having a lower baseline of fluorescence. 
Lesioned tissue showed a major contribution from proteins, increase in collagen content 
(with proline and hydroxy proline also present) and two types of calcifications, type I 
(calcium oxalate) and type II (hydroxyapatite), which were found in two differing groups 
of spectra. Carotenoids, departing from the reviewed literature, were not prevalent. By 
that, carotenoids were not even found in the determined healthy tissue and one of the 
lesioned tissues had a minor presence. The way the samples were preserved, fixed in 
formaldehyde, might explain this case. 
The increase in information regarding specific regions of the spectrum might be 
due to the equipment used and not on the technique itself. Some of this information, if 
reproduced and validated can increase the accuracy of future Raman spectroscopy 
discrimination regarding tumorous tissue. 
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It also opens the path for future work, based on the ground work already done, pursuing 
to fully develop an in vivo Raman spectroscopy endoscope. A possible roadmap can be 
as follows: 
 
• Use the knowledge gained through this work and devise a miniaturized/portable 
system. 
• Develop a filter tip to apply into optical fibres. 
• Incorporate this fibre onto a spectrometer and analyse reference materials and 
improve the system. 
• Step up into fixed breast samples. 
• Afterwards into fresh samples. 
• Validate the incorporation of such a system into an endoscope in a medical 
environment.
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Appendix A - Brief review of endoscopy 
based on optical fibres 
 
A.1 Endoscopy using solid core fibres 
 
In the 1990’s there was still studies of optical fibre properties being performed as 
seen in [43] where an analysis of background fibre emission for a typical silica fibre, a 
forward-scattering fibre geometry study and the determination of the dependence of 
sensitivity on the type of optical termination and separation is performed. Relevance to 
this dissertation is present due to fibre background noise analysis and throughput 
dependence.  
Most reports of standard silica optical fibre usage for Raman spectroscopy date 
back from 1995-2000 [43-49], there was afterwards a shift for other optical fibres. Many 
of the reported works use a kind of fibre bundle geometry where there is a central fibre 
for delivery of laser signal and multiple fibres for collection of Raman signal surrounding 
it. 
With Berger et al., [44], a 50 µm core diameter wide fibre was used for laser 
delivery and a 100 µm diameter for collection of signals. A tuneable diode laser emitting 
at 830 nm with 200 mW optical power was the source. The laser was then 
holographically bandpass-filtered and coupled into a 50 µm core diameter optical fibre. 
The fibre guided light onto a dichroic beam splitter apparatus that imaged the excitation 
fibre's output 1:1 onto the samples. The Raman signal emerging from the sample surface 
1:1 imaged onto a collection fibre with a core diameter of 100 µm and numerical aperture 
of 0.29. The collected signal passed through a holographic notch filter which had an 
optical attenuation of four at the excitation wavelength and a transmission of 80% of the 
scattered Raman light. Then, was coupled to a single-stage f/1.8 spectrograph 
(Holospec, Kaiser Optical Systems) equipped with a transmissive holographic grating 
and a back-thinned, 512x512 element, LN2 cooled charge coupled device, CCD, 
(Tektronix, Princeton Instruments). Spectra from dissolved gases in PBS was gathered 
and their concentrations were measured using Raman spectroscopy. The schematic is 
presented in Figure 17. 
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Figure 17. Schematic of the Raman spectroscope. Adapted from [44]. 
 
Following up, part of the group [45] employed a 6x1 fibre bundle geometry with 
all fibres being 100µm wide. Laser source and spectrograph system were the same as 
in [44]. This time glucose, lactic acid and creatinine concentrations in a phosphate-
buffered saline solution were measured. 
Raman endoscopic systems built for clinical environment were also pursued, as 
seen in Brennan et al., [46], where two systems were built, namely a “Laboratory system” 
and a “Clinical system”. The first used an Argon laser pumped Ti:Sapphire system 
(Coherent Innova 90/Spectra Physics 3900S) outputting close to 350 mW of optical 
power at 830 nm. No optical fibres were utilized on this system. The “Laboratory system” 
used a diode laser (SDL 8630) also emitting at 830 nm. Light was both delivered and 
collected via a “5 French” (~1.7 mm diameter) 3 m long optical probe that was arranged 
in a 6x1 optical fibre bundle geometry (Fiberguide Ahnydroguide G). All fibres had 
200 µm of diameter and were coupled to a f/1.8 (Holospec, Kaiser) spectrometer.  In the 
same time period Mahadevan-Jansen et al. [47], built a probe using a multimode silica 
fibre with 200 µm core diameter for the delivery fibre and 100 µm wide collection fibres. 
A diode laser outputting 15 mW of optical power at 789 nm was utilized. Spot size at 
analyte surface was 900 µm. One of the fibres guided a 632.8 nm He-Ne laser to help 
guiding the probe. The objective was to develop a compact fibre optic probe to measure 
near infrared Raman spectra of human cervical tissue in vivo for the clinical diagnosis of 
cervical precancer. 
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Various works from Shim et al. [48-50] also developed an optical fibre Raman 
endoscope. In [48] the probe used a 6x1 optical fibre bundle geometry, the diameters for 
core, cladding and the buffer were 200 µm, 240 µm and 270 µm, respectively (Polymicro 
Tehcnologies, Phoenix, AZ, USA). A diode laser (SDL, San Jose, CA, USA) was utilized 
in the 778 ± 10nm band. For spectrographic system a f/1.8 (Holospec, Kaiser Optical 
Systems) was also used. The same system was updated in [49] where a 7x1 bundle of 
low-OH fibres was used. The width of the fibres were 400 µm and 300 µm for the delivery 
and collection fibres, respectively, and the probe length was 1.5m. Filters where 
introduced at 0.0025m from the tip, a bandpass for the delivery fibre and long-pass filters 
for collection fibres, hereby the system was named IFP (Internally filtered probe) (Figure 
18). Laser source and spectrographic system were the same as in [9]. The following year 
[50] uses the described system together with a 785 nm, ~100 mW incident power, diode 
laser (Model 8630, SDL, San Jose, CA) to test viability in gastrointestinal endoscopy.  
Motz et al. [51], also used a probe that can be seen as an IFP (Figure 18, left 
side). Fibres with 200 µm in core diameter and a 15x1 bundle geometry were used. Both 
filters and a sapphire ball lens where attached to the bundle tip. The built probe was 4 m 
long and 3 mm in tip diameter.  A diode laser (Process Instruments, Salt Lake City, Utah) 
outputting close to 100 mW of optical power at 830 nm was utilized. Spectrograph 
system was a f/1.8i (Holospec, Kaiser Optical Systems). Tissue models and in vitro 
samples were imaged. Another IFP (Figure 18, right side) is seen in Komachi et al. [52], 
where an 8x1 fibre (SF112 UV, Japan) bundle was employed, where a fibre core with 
114 µm in diameter was used. A Ti:Sapphire, background-free, electronically tuned laser 
outputting ~7 mW of optical power at 720 nm was also used. The spectrograph system 
was a UV-visible-near-IR spectrometer (UV 3100PC, Shimadzu Company, Kyoto, 
Japan). An array of biological samples where tested with this probe. 
43 
 
 
Figure 18. Schematics of Internally Filtered Probes (IFP). Left: A 15x1 geometry fibre bundle with a short-pass filter added 
on delivery fibre and long-pass filters to the collection fibres, adapted from [51]; Right: A 8x1 fibre bundle with long-pass 
and bandpass filters added to the collection and delivery fibres, adapted from [52]. 
A different system from an endoscopic one was described by Ashok et al. [53], 
where a microfluidic Raman probe inserted on a polydimethylsiloxane (PDMS) chip was 
built. A single delivery and collection fibres of low HO (Polymicro Technologies, AZ, USA) 
with 200 µm in diameter were used. A diode laser (Laser2000, (UK) Ltd.) outputted up 
to 200 mW maximum of optical power at 785nm and the signal was analysed in a 
spectrometer (Shamrock SR-303i, Andor Technology). The PDMS chip was fabricated 
with conventional soft lithographic techniques. Urea was measured and influence of flow 
on count rate was tested with ethanol. 
Saar et al. [54], described a Raman fibre endoscopy probe that used both Stokes 
and pump beams. A single-mode polarization-maintaining fibre was used (PM780-HP, 
Thorlabs). The laser utilized was a mode locked Nd:YVO4 laser at 1064 nm with 7 ps 
pulses with repetition rate of 80 MHz. Part of the laser output was frequency doubled 
and synchronously pumped by an optical parametric oscillator (Levante Emerald, APE 
GmbH), which generated a tuneable 800 nm pump beam. Signal acquisition was done 
with a photodetector and lock-in amplifier. Mouse tissue samples were analysed with this 
probe. 
 
A.2 Endoscopy using Photonic crystal fibres 
 
Photonic crystal fibres (PCF) where first discovered in the 1990’s [55]. They differ 
from solid silica fibres by having air channels etched into them. The periodicity of the 
aligned air holes provides a confinement of light on the fibre core. There are reports of 
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many types of PCF, only two of them will be subject of analysis on this dissertation, 
namely: conventional solid core PCF [56] and hollow core photonic crystal fibres (HC-
PCF) [57-64]. Solid core PCF (Figure 19. a)) are micro structured fibres where there is a 
solid silica core and the micro structured cladding of silica and air holes diminishes the 
surrounding overall refractive index, guiding light trough the silica core. On the other 
hand, HC-PCF (Figure 19. b), c)) are characterized by having an air core and a periodic 
structure in the cladding that acts as a Bragg reflector, being then a true photonic crystal, 
confining light to the hollow core by photonic bandgap guiding (PBG). The earliest works 
reporting usage of HC-PCF for Raman spectroscopy date back to 2002-2006 [56, 57]. 
 
Figure 19. a) Solid core PCF; b) HC-PCF; c) Kagomé Lattice HC-PCF. 
 
Benabid et al., [57] is one of the earliest works, in 2002. In it, a 1m long Kagome 
lattice HC-PCF with 15 µm core diameter was built. The fibre was filled with hydrogen 
gas and pumped with a Q-switched single-mode frequency-doubled Nd:YAG laser that 
operated at 532 nm with 6 ns pulses and 20 Hz repetition rate. Stokes and coherent anti-
Stokes generation threshold and also pump-to-Stokes conversion efficiency was 
observed and analysed. Followed by Pristinski et al., [56]., that used a micro structured 
solid core fibre with a 2.5 µm silica core, with 126 3.5 µm air holes. A custom-made 
stainless-steel chamber facing fused silica windows sealed the fibre ends. The total 
probe length was of 0.2667 m. Coupled to it was a continuous wave Argon-ion laser that 
emitted 8mW of optical power at 488 nm. A neat acetonitrile solution filled the 
microstructure air holes and was analysed with a spectrometer with <100 ms of 
exposition time. On the same year Konorov et al. [58], a HC-PCF with 19 air holes was 
utilized, the fibre had an outer diameter of 84 µm, was 0.30 m long and with high 
transmission near 532 nm.  The laser (Verdi V-10 Coherent) emitted 50 mW of optical 
power at 532 nm. The collection fibre was a standard silica core fibre, with 400 µm outer 
diameter and was 0.50 m in length. A spectrometer (Model 2061) was used to analyse 
Raman spectra of ethanol 95%(w/w). 
45 
 
In 2010, Balu et al. [59], tested three different fibres to deliver laser pulses. A 
single mode fused silica (HI 780, Corming), with a mode field diameter of ~4.8 µm and 
0.40 m long, the second was a double clad PCF (A/S DC-165-16 PASSIVE, Crystal 
Fibre) mode field diameter of ~16 µm and 0.80 m long, the third was a large mode area 
PCF (LMA-20, Crystal Fibre) mode field diameter of ~20 µm and 0.5 m in length. For 
collection a multi-mode fibre (M28L01, ThorLabs) with 400 µm in core diameter and 1 m 
long was utilized. The laser system for the pump beam was a Ti:Sapphire oscillator, with 
280 fs pulses at 76 MHz and 817 nm with 35 mW optical power. Stokes beam was 
generated by a mode locked laser source with 7.5 ps pulses at 76 MHz and 1064 nm 
with 25 mW optical power. A spectrometer (USB 4000 - VIS - NIR Miniature) monitored 
the output spectrum of each delivery fibre and a photomultiplier tube (R7400U-20, 
Hamamatsu) collected the signal. Images of adipocytes of fresh sample mouse ear 
(CD1/CD7 black wild), rabbit skin (Pathogen free, New Zealand) and lipid distribution of 
meibomian gland and eyelids of 2-month-old mice in 2% paraformaldehyde and PBS 
were generated with 512x512 pixels at 2 s per frame. 
The year after, Brustlein et al. [60], employed a pure silica HC-PCF with 7 cells 
(air holes) counting the core, 2260 µm2 was the collection cross section, with 200 nm 
width of air cladding struts, a diameter of 103 µm and with low loss from 950 nm to 
1150 nm. The pump beam was produced from an optical parametric oscillator tuned from 
962 nm to 971 nm, outputting 100 mW while the Stokes beam originated in a mode 
locked Nd:YVO with 7 ps pulses at 1064 nm with 100 mW. An avalanche photodiode 
detector (APD, Hamamatsu C5460) and a fast lock in amplifier were used to analyse 
spectra. The objective was to demonstrate coherent anti-Stokes Raman scattering and 
stimulated Raman scattering in an “endoscope-like” scheme using a double-clad hollow 
core photonic crystal fibre. 
A 7 cell HC-PCF is also used by Khetani et al. [61], the fibre had 10.6 µm core 
diameter (+- 1 µm), a clad channel diameter of 3 µm (+- 1 µm) and was 0.10 m long. A 
laser diode with a central wavelength of 785 nm and 100 mW optical power was used. 
Together with a f/1.8i (Holospec, Kaiser Optical Systems) spectrometer system a 
pressure driven flow system was built and ethanol and isopropanol in concentrations 
from 5% to 60% in deionized water were analysed.  
Other research groups [62-64] developed, studied and utilized a Kagomé lattice 
HC-PCF in a Raman spectroscopy endoscope. On a first stage [62] a 1.5 m long with 
undisclosed specifications Kagomé lattice HC-PCF (Figure 21. a)) was used and coupled 
to a He-Ne laser at 632.8 nm delivering 6 mW of optical power. The laser was coupled 
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to the fibre by a 150 mm lens with numerical aperture of 0.02 (same as fibre) and then 
focused onto a 1 cm quartz cuvette by 2 achromatic doublets with 25 mm in focal length. 
A dichroic mirror separated Raman scatter light from reflected and elastically scattered 
one (Omega 650 DRLP) plus a long pass filter (Omega 640 AELP) and bandpass filter 
(Kaiser Optics HNF-632.8-1.0). Spectrometer was a Horiba JobinYvon iHR320 with a 
Peltier-cooled CCD camera. Each spectrum consisted of 4 acquisitions of 10 seconds 
each. Schematic of the system is present in Figure 20. 
 
 
Figure 20. Schematic of Raman spectroscopic system. Adapted from [62]. 
 
Following it, a single mode Kagome lattice HC-PCF was utilized [63], 
specifications of the fibre are disclosed as being 278 µm in diameter with a 20µm wide 
core, the laser source ranged from 780 nm to 815 nm at around 200 mW of optical 
power. The objective was confirming the presence of parasitic signals and search 
parameters that are parasitic signal free. In the end [64], a Raman endoscope was built 
by using a double clad Kagomé lattice HC-PCF (Figure 21. b)). The fibre had an outer 
diameter of 327 µm and a core diameter of 20 µm wherein light propagated in a single 
transverse mode. A 30 µm microsphere was introduced to reduce laser spot on incident 
surface, from 15 µm to 1 µm, enabling high-resolution nonlinear imaging. Laser source 
for pump and Stokes beams was obtained from a tuneable multi-wavelength laser 
system (Discovery, Coherent) that provided two pulse trains at 80 MHz. The pump beam 
was at 800 nm and 100 fs wide while Stokes beam was at 1040 nm and 160 fs wide. 
Coherent anti-Stokes Raman Scattering (CARS), Second harmonic generator (SHG) 
and two-photon excited fluorescence (TPEF) images were built and displayed in real 
time using custom LabVIEW software based on an open-loop image reconstruction 
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algorithm with submicron spatial resolution over a field of view of up to 320 µm at a rate 
of 0.8 frames per second. 
 
Figure 21. Scanning electron micrograph of fibre utilized a), adapted from [62]; b) 1: scanning electron micrograph of 
single mode, double clad Kagomé lattice HC-PCF, 2: close up image of microsphere utilized, 3 and 4: laser spot images 
without microsphere and with added microsphere, adapted from [64]. 
Closing Remarks 
 
Raman spectroscopy using optical fibres is being researched for some time, with 
the major contribution using mono mode fibres being from the period of 1995 – 2000. 
The major advancements when using mono mode fibres would have to be, in my opinion, 
the fibre bundle configuration increasing the collecting area without increasing as much 
the complexity and the development of internal filtered probes, that helped to diminish 
signal noise while also miniaturizing more the probing apparatus.  
Afterwards, Raman spectroscopy studies started using micro structured fibres. 
Namely PCF, HC-PCF and Kagomé lattice fibre. This type of fibres have high collecting 
area and their structure acts as a filter. While also having the advantage of being a single 
fibre.  
If pursuing to develop a Raman spectroscopy system with portability in mind or 
with the ability for being applied in a clinical environment, basing on the research done 
the remarks would be: using 785nm excitation wavelength, it appears to be a suitable 
wavelength as seen in the works of Bergholt et al. [16, 20, 22, 27], and others; a double-
clad Kagomé or HC-PCF fibre with either internal filtering or a filtered tip coupled to the 
fibre to reduce parasitic signal coming in and out of the probe; the Raman signal collected 
would be divided into two bands, being the first from 800-1200cm-1 and the second from 
1200-1800cm-1 due to signal inversion around this wavenumber. The possible fingerprint 
peaks to look for would be (in cm-1): 1004, 1335, 1445, 1618 and 1655 for being recurring 
peaks across multiple works.  
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